Results beat expectations
According to Reuters, citing LSEG data, Merck's key third-quarter figures were:
- Revenue of $18.1 billion, beating the average estimate of $17.3 billion.
- Adjusted earnings of $2.49 per share, ahead of expectations of $2.08.
- About $550 million of growth came from drug purchases made earlier than expected.
- Pulmonary arterial hypertension drug Winrevair generated $694 million in sales, up 94% year on year.
Merck shares rose nearly 3% in premarket trading. The stock closed at $140.93 on October 28 and is up around 34% this year, outperforming the wider market.
Keytruda keeps leading
Sales of immunotherapy Keytruda, one of the world's best-selling drugs, rose 6% from a year earlier to $8.6 billion, beating analysts' estimates of $8.0 billion. Those sales included $830 million from the new subcutaneous version, Keytruda QLEX, approved late last year.
The subcutaneous version shortens treatment time compared with intravenous infusion and is seen as a key strategy to extend Keytruda's commercial life before biosimilars arrive.

















